Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 1.00 |
| ▸ | DRD3 | P35462 | 8/20 | 1.00 |
| ▸ | DRD4 | P21917 | 3/20 | 1.00 |
| ▸ | DRD1 | P21728 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | DRD5 | P21918 | 1/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.81 |
| ▸ | TSHR | P16473 | 1/20 | 0.81 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.81 |
| ▸ | THPO | P40225 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 5-Oh-Dpat SCHEMBL5705486 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4DRD1HTR1A | |
| 5-Oh-Dpat SCHEMBL17446178 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4DRD1HTR1A | |
| 5-Oh-Dpat SCHEMBL30201073 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4DRD1HTR1A | |
| 5-Oh-Dpat SCHEMBL279021 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4DRD1HTR1A | |
| SCHEMBL21262950 | 0.94 | DRD2 (0.90) | DRD2DRD3DRD4DRD1HTR1A | |
| SCHEMBL21083262 | 0.94 | DRD2 (0.90) | DRD2DRD3DRD4DRD1HTR1A | |
| SCHEMBL29062563 | 0.94 | DRD2 (0.88) | DRD2DRD3DRD4DRD1HTR1A | |
| SCHEMBL24314254 | 0.92 | DRD2 (0.91) | DRD2DRD3DRD4DRD1HTR1A | |
| SCHEMBL11198430 | 0.91 | DRD2 (0.84) | DRD2DRD3DRD4DRD1HTR1A | |
| SCHEMBL11199129 | 0.91 | DRD2 (0.84) | DRD2DRD3DRD4DRD1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485181-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | SERINA THERAPEUTICS (AL), INC. (US) | 2025-12-02 | — | — | US | claimed |
| US-12383625-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | SERINA THERAPEUTICS (AL), INC. (US) | 2025-08-12 | — | — | US | claimed |
| US-12383626-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | SERINA THERAPEUTICS (AL), INC. (US) | 2025-08-12 | — | — | US | claimed |
| US-20240316208-A1 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | SERINA THERAPEUTICS (AL), INC. (US) | 2024-09-26 | — | — | US | claimed |
| US-20240293560-A1 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | SERINA THERAPEUTICS (AL), INC. (US) | 2024-09-05 | — | — | US | claimed |
| US-11944618-B2 | Subcutaneous delivery of polymer conjugates of therapeutic agents | SERINA THERAPEUTICS, INC. (US) | 2024-04-02 | — | — | US | claimed |
| US-20230009076-A1 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | SERINA THERAPEUTICS, INC. (US) | 2023-01-12 | — | — | US | claimed |
| EP-3990026-A1 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | Serina Therapeutics, Inc. (US) | 2022-05-04 | — | — | EP | claimed |
| US-11298350-B2 | Subcutaneous delivery of polymer conjugates of therapeutics agents | SERINA THERAPEUTICS, INC. (US) | 2022-04-12 | — | — | US | claimed |
| CN-114258309-A | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | 塞瑞纳治疗公司 | 2022-03-29 | — | — | CN | claimed |
| US-20260131012-A1 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | SERINA THERAPEUTICS (AL), INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-12485181-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | SERINA THERAPEUTICS (AL), INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-12428408-B2 | Fused heterocyclic mescaline derivatives | Enveric Biosciences Canada Inc. (CA) | 2025-09-30 | — | — | US | disclosed |
| US-12383626-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | SERINA THERAPEUTICS (AL), INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-12383625-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | SERINA THERAPEUTICS (AL), INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20220354841-A1 | SUBCUTANEOUS DELIVERY OF POLYMER CONJUGATES OF THERAPEUTIC AGENTS | SERINA THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | US | disclosed |
| EP-3990026-A1 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | Serina Therapeutics, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| US-11298350-B2 | Subcutaneous delivery of polymer conjugates of therapeutics agents | SERINA THERAPEUTICS, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| CN-114258309-A | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | 塞瑞纳治疗公司 | 2022-03-29 | — | — | CN | disclosed |
| US-11285147-B2 | Neuroprotective agents for treatment of neurodegenerative diseases | WAYNE STATE UNIVERSITY (US) | 2022-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12383625-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | CYP3A5, SPOP, CYP2C19 | DRD2 662/4885DRD3 695/4885DRD4 598/4885 |
| US-20230009076-A1 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | CYP3A5, CYP2C19, CYP3A7 | DRD2 520/4885DRD3 644/4885DRD4 420/4885 |
| US-11944618-B2 | Subcutaneous delivery of polymer conjugates of therapeutic agents | CD44, CD47, LNPEP | DRD2 4535/4885DRD3 4646/4885DRD4 4501/4885 |
| US-12428408-B2 | Fused heterocyclic mescaline derivatives | UGT2B7, CYP3A5, CYP2C19 | DRD2 51/4885DRD3 78/4885DRD4 158/4885 |
| US-12485181-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | CYP3A5, CYP2C19, CYP3A7 | DRD2 520/4885DRD3 644/4885DRD4 420/4885 |
| US-20240293560-A1 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | CYP3A5, SPOP, CYP2C19 | DRD2 662/4885DRD3 695/4885DRD4 598/4885 |
| US-11298350-B2 | Subcutaneous delivery of polymer conjugates of therapeutics agents | CD44, CD47, LNPEP | DRD2 4300/4885DRD3 4476/4885DRD4 4298/4885 |
| US-11285147-B2 | Neuroprotective agents for treatment of neurodegenerative diseases | PARK7, SMN1; SMN2, CLN6 | DRD2 283/4885DRD3 377/4885DRD4 192/4885 |
| US-20260131012-A1 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | CYP2C19, CYP2C9, CYP3A5 | DRD2 949/4885DRD3 1124/4885DRD4 1293/4885 |
| US-12383626-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | CYP3A5, SPOP, CYP2C19 | DRD2 662/4885DRD3 695/4885DRD4 598/4885 |
| US-20240316208-A1 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | CYP3A5, SPOP, CYP2C19 | DRD2 662/4885DRD3 695/4885DRD4 598/4885 |
| US-20220354841-A1 | SUBCUTANEOUS DELIVERY OF POLYMER CONJUGATES OF THERAPEUTIC AGENTS | CD44, CD47, LNPEP | DRD2 4521/4885DRD3 4643/4885DRD4 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.